Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-16T03:27:33.058Z Has data issue: false hasContentIssue false
  • English
  • Français

A long-term care center interdisciplinary education program for antipsychotic use in dementia: program update five years later

Published online by Cambridge University Press:  30 November 2011

Stephen Vida ,
Johanne Monette ,
Machelle Wilchesky ,
Michèle Monette ,
Ruby Friedman ,
Anh Nguyen ,
Dolly Dastoor ,
Gabriela Cristache ,
Nadia Sourial  and
Lucie Tremblay
...Show all authors
Stephen Vida
Affiliation:
Donald Berman Maimonides Geriatric Centre, McGill University, Montreal, Quebec, Canada McGill University Health Centre Department of Psychiatry, Montreal, Quebec, Canada
Johanne Monette
Affiliation:
Donald Berman Maimonides Geriatric Centre, McGill University, Montreal, Quebec, Canada Division of Geriatric Medicine, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada Solidage-McGill University-Université de Montréal Research Group on Frailty and Aging, Center for Clinical Epidemiology and Community Studies, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
Machelle Wilchesky
Affiliation:
Donald Berman Maimonides Geriatric Centre, McGill University, Montreal, Quebec, Canada Center for Clinical Epidemiology and Community Studies, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
Michèle Monette
Affiliation:
Donald Berman Maimonides Geriatric Centre, McGill University, Montreal, Quebec, Canada Solidage-McGill University-Université de Montréal Research Group on Frailty and Aging, Center for Clinical Epidemiology and Community Studies, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
Ruby Friedman
Affiliation:
Donald Berman Maimonides Geriatric Centre, McGill University, Montreal, Quebec, Canada Division of Geriatric Medicine, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada
Anh Nguyen
Affiliation:
Donald Berman Maimonides Geriatric Centre, McGill University, Montreal, Quebec, Canada
Dolly Dastoor
Affiliation:
Geriatric Psychiatry Program, Douglas Mental Health University Institute, Montreal, Quebec, Canada
Gabriela Cristache
Affiliation:
Donald Berman Maimonides Geriatric Centre, McGill University, Montreal, Quebec, Canada
Nadia Sourial
Affiliation:
Solidage-McGill University-Université de Montréal Research Group on Frailty and Aging, Center for Clinical Epidemiology and Community Studies, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
Lucie Tremblay
Affiliation:
Donald Berman Maimonides Geriatric Centre, McGill University, Montreal, Quebec, Canada
Brian Gore*
Affiliation:
Donald Berman Maimonides Geriatric Centre, McGill University, Montreal, Quebec, Canada
*
Correspondence should be addressed to: Brian Gore, Donald Berman Maimonides Geriatric Centre, 5795 Caldwell Avenue, Montreal, Quebec, H4W 1W3, Canada. Phone: +1 (514) 483–2121. Email: [email protected].
Get access Rights & Permissions [Opens in a new window]

Abstract

Background: While antipsychotic (AP) medications are frequently used in long-term care, current evidence suggests that the risks may offset the benefits, necessitating periodic reassessment of their use. The aims of this present study were: (1) to assess rates of AP use five years after our first intervention to determine the long-term impact; and (2) to implement an updated AP reduction educational intervention program at the same center five years later in order to determine whether AP use could be further reduced.

Methods: Participants were residents with dementia receiving AP medication. The educational program component included separate lectures on pharmacologic and non-pharmacologic treatment of behavioral and psychological symptoms of dementia (BPSD). Completion of the Nursing Home Behavior Problems Scale (NHBPS), physician interviews concerning AP treatment plans for subjects with dementia, and AP administration and dose assessment occurred both at baseline and again between four to five months after the educational program.

Results: Of 308 long-term residents with dementia, 53 (17.2%) were receiving regular APs, primarily for agitation, aggressivity, other behavioral problems and psychosis. Of these, six died and one was transferred, leaving 46 participants. At five months, ten (21.7%) residents were no longer receiving APs and seven (15.2%) were on a lower dose; thus, 17 (37.0%) were either discontinued or on a lower dose. There was no worsening of NHBPS scores.

Conclusion: Despite the low prevalence (17.2%) of AP users at the beginning of the current study compared to that observed five years prior (30.5%), it is still possible to further decrease the proportion of users.

Keywords

antipsychotic agentsdementialong-term careprescribing educational programprescribing interventiongeriatrics
Type
Research Article
Information
International Psychogeriatrics , Volume 24 , Issue 4 , April 2012 , pp. 599 - 605
Copyright
Copyright © International Psychogeriatric Association 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ballard, C. et al. (2008). A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Medicine, 5, e76.CrossRefGoogle ScholarPubMed
Ballard, C. et al. (2009). The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurology, 8, 151–157.CrossRefGoogle ScholarPubMed
Burke, W. J. (1991). Neuroleptic drug use in the nursing home: the impact of OBRA. American Family Physician, 43, 2125–2130.Google ScholarPubMed
Canadian Pharmacists Association (2011). Compendium of Pharmaceuticals and Specialties. Ottawa: Canadian Pharmacists Association.Google Scholar
Centers for Medicare and Medicaid Services (2006). Revised Long-Term Care Facility Resident Assessment Instrument User's Manual. (Rev. 70, 01–07-11). Available at: http://www.cms.gov/manuals/Downloads/som107ap_pp_guidelines_ltcf.pdf.Google Scholar
Chen, Y., Briesacher, B. A., Field, T. S., Tjia, J., Lau, D. T. and Gurwitz, J. H. (2010). Unexplained variation across US nursing homes in antipsychotic prescribing rates. Archives of Internal Medicine, 170, 89–95.CrossRefGoogle ScholarPubMed
Institute of Medicine, Committee on Nursing Home Regulation (1986). Improving the Quality of Care in Nursing Homes. Washington, DC: National Academy Press.Google Scholar
Jeste, D. V., Rockwell, E., Harris, M. J., Lohr, J. B. and Lacro, J. (1999). Conventional vs. newer antipsychotics in elderly patients. American Journal of Geriatric Psychiatry, 7, 70–76.CrossRefGoogle ScholarPubMed
Kamble, P., Chen, H., Sherer, J. and Aparasu, R. R. (2008). Antipsychotic drug use among elderly nursing home residents in the United States. American Journal of Geriatric Pharmacotherapy, 6, 187–197.CrossRefGoogle ScholarPubMed
Knol, W., Van Marum, R. J., Jansen, P. A., Souverein, P. C., Schobben, A. F. and Egberts, A. C. (2008). Antipsychotic drug use and risk of pneumonia in elderly people. Journal of the American Geriatrics Society, 56, 661–666.CrossRefGoogle ScholarPubMed
Lee, P. E. et al. (2005). Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. Journal of the American Geriatrics Society, 53, 1374–1379.CrossRefGoogle ScholarPubMed
Liperoti, R. et al. (2005). Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest. Archives of Internal Medicine, 165, 696–701.CrossRefGoogle ScholarPubMed
Monette, J. et al. (2008). Effect of an interdisciplinary educational program on antipsychotic prescribing among nursing home residents with dementia. International Journal of Geriatric Psychiatry, 23, 574–579.CrossRefGoogle ScholarPubMed
Monette, J., Monette, M., Champoux, N., Galbaud Du Fort, G. and Wolfson, C. (2009). Efficacy and adverse effects of antipsychotic medications among elderly persons with dementia. La Revue de Gériatrie, 23–31.Google Scholar
Ostini, R. et al. (2009). Systematic review of interventions to improve prescribing. Annals of Pharmacotherapy, 43, 502–513.CrossRefGoogle ScholarPubMed
Ray, W. A., Blazer, D. G., Schaffner, W. and Federspiel, C. F. (1987). Reducing antipsychotic drug prescribing for nursing home patients: a controlled trial of the effect of an educational visit. American Journal of Public Health, 77, 1448–1450.CrossRefGoogle ScholarPubMed
Ray, W. A., Taylor, J. A., Lichtenstein, M. J. and Meader, K. G. (1992). The Nursing Home Behavior Problem Scale. Journal of Gerontology, 47, M9–M16.CrossRefGoogle ScholarPubMed
Ray, W. A., Meredith, S., Thapa, P. B., Meador, K. G., Hall, K. and Murray, K. T. (2001). Antipsychotics and the risk of sudden cardiac death.[see comment]. Archives of General Psychiatry, 58, 1161–1167.CrossRefGoogle ScholarPubMed
Roberts, M. S. et al. (2001). Outcomes of a randomized controlled trial of a clinical pharmacy intervention in 52 nursing homes. British Journal of Clinical Pharmacology, 51, 257–265.CrossRefGoogle ScholarPubMed
Rochon, P. A. et al. (2005). Atypical antipsychotics and parkinsonism. Archives of Internal Medicine, 165, 1882–1888.CrossRefGoogle ScholarPubMed
Rochon, P. A. et al. (2007). Variation in nursing home antipsychotic prescribing rates. Archives of Internal Medicine, 167, 676–683.CrossRefGoogle ScholarPubMed
Ruths, S., Straand, J., Nygaard, H. A., Bjorvatn, B. and Pallesen, S. (2004). Effect of antipsychotic withdrawal on behavior and sleep/wake activity in nursing home residents with dementia: a randomized, placebo-controlled, double-blinded study. The Bergen District Nursing Home Study. Journal of the American Geriatrics Society, 52, 1737–1743.CrossRefGoogle Scholar
Ruths, S., Straand, J., Nygaard, H. A. and Aarsland, D. (2008). Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study. The Bergen District Nursing Home Study (BEDNURS). International Journal of Geriatric Psychiatry, 23, 889–895.CrossRefGoogle Scholar
Schneider, L. S., Dagerman, K. S. and Insel, P. (2005). Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA, 294, 1934–1943.CrossRefGoogle ScholarPubMed
Schneider, L. S. et al. (2006). Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. New England Journal of Medicine, 355, 1525–1538.CrossRefGoogle ScholarPubMed
Semla, T. P., Palla, K., Poddig, B. and Brauner, D. J. (1994). Effect of the Omnibus Reconciliation Act 1987 on antipsychotic prescribing in nursing home residents. Journal of the American Geriatrics Society, 42, 648–652.CrossRefGoogle ScholarPubMed
Thapa, P. B., Meador, K. G., Gideon, P., Fought, R. L. and Ray, W. A. (1994). Effects of antipsychotic withdrawal in elderly nursing home residents. Journal of the American Geriatrics Society, 42, 280–286.CrossRefGoogle ScholarPubMed
Trifiro, G., Spina, E. and Gambassi, G. (2009). Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile? Pharmacological Research, 59, 1–12.CrossRefGoogle ScholarPubMed
Weiden, P. J. (2007). EPS profiles: the atypical antipsychotics are not all the same. Journal of Psychiatric Practice, 13, 13–24.CrossRefGoogle Scholar
Westbury, J., Jackson, S., Gee, P. and Peterson, G. (2010). An effective approach to decrease antipsychotic and benzodiazepine use in nursing homes: the RedUSe project. International Psychogeriatrics, 22, 26–36.CrossRefGoogle ScholarPubMed